In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), with a price target of $25.00. The company’s shares closed yesterday at $15.40.
According to TipRanks, Pachaiyappan is a 2-star analyst with an average return of -0.1% and a 50.00% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Galecto, Entrada Therapeutics Inc, and Aeterna Zentaris.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entrada Therapeutics Inc with a $25.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
TRDA market cap is currently $511.2M and has a P/E ratio of -5.98.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRDA in relation to earlier this year. Most recently, in June 2023, WENTWORTH KORY JAMES, the CFO of TRDA bought 8,790.00 shares for a total of $18,459.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Read More on TRDA:
